News PTC's muscular dystrophy drug can stay on EU market - regula... But PTC must conduct further trial to confirm Translarna's benefits.
News Biogen/Ionis could launch rare disease drug within weeks Companies prepare for launch of Spinraza after phase 3 success.
News Vtesse's rare disease drug set for UK early access Vtesse drug "promising" treatment for NPC disease, says regulator.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
